A randomized, two-part, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZGN-1061 in healthy normal weight, overweight and obese male and female volunteers

Completed

• Conditions: Obesitas; Obesity

• Registration Number: NL-OMON42985
• Lead Sponsor: Zafgen, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 72

Inclusion Criteria

healthy male or female subjects
18-55 years, inclusive
BMI: SAD segment: 23.0 to <30.0 kg/m2, MAD segment: 30.0-40.0 kg/m2, inclusive

Exclusion Criteria

Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. Donation or loss of more than 100 mL of blood within 60 days prior to (the first)
drug administration. Donation or loss of more than 1.5 liters of blood (for male subjects) / more than 1.0 liters of blood (for female subjects) in the 10 months prior to (the first) drug administration in the current study

Study & Design

• Study Type: Interventional
• Study Design: Not specified